Geron Corp (GERN)

$1.28 -0.07 (-5.19%)
Market Cap 861.32M
Revenue (ttm) 76.99M
Net Income (ttm) -174.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -226.74%
Debt to Equity Ratio 0.46
Volume 8,908,199
Avg Vol 8,674,090
Day's Range N/A - N/A
Shares Out 638.02M
Stochastic %K 5%
Beta 0.57
Analysts Sell
Price Target $3.56

Company Profile

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 473 7700
Address:
919 East Hillsdale Boulevard, Suite 250, Foster City, United States
ZoeyTanner
ZoeyTanner Oct. 7 at 10:48 AM
$GERN Nothing here, move on. The longest wait for anything continues. The long goodbye may be in store for Harout and for BOD choice.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 7 at 1:44 AM
To us it appears that since commercial-stage oncology trades at significantly lower revenue multiples than non-oncology, oncology offers the better risk v. reward profile now that the XBI is nearing multi-year highs. Bios in both peer groups have near-tern data reads that may manifest in higher/lower revenues depending on the outcomes ($GERN $IBRX) Are we wrong? This is not investment advice. $KALV $CRMD $SLNO
0 · Reply
ZdP2
ZdP2 Oct. 6 at 10:11 PM
$GERN Seems like it wants to fill the gap to 1.2 before we go back up again. Anything below 1.3 is a great buying opportunity imho. GLTA !
0 · Reply
ZdP2
ZdP2 Oct. 6 at 7:57 PM
$GERN Large bids again...
0 · Reply
Polip
Polip Oct. 6 at 7:12 PM
$GERN idiotic short selling
2 · Reply
ZoeyTanner
ZoeyTanner Oct. 6 at 6:56 PM
$GERN Extremely bullish..give me a break..the loser of all time here with no ceo
0 · Reply
AxelWiz
AxelWiz Oct. 6 at 6:10 PM
$GERN I don’t even know why I keep looking here! This went from one of my favorite investments to one of my most hated investments, even though I’m not willing to part with it for another 3-5y
1 · Reply
ZdP2
ZdP2 Oct. 6 at 5:43 PM
$GERN About to bounce here again imo.
1 · Reply
Cello69
Cello69 Oct. 6 at 5:22 PM
$GERN Fucking worthless POS
1 · Reply
ZoeyTanner
ZoeyTanner Oct. 6 at 4:46 PM
$GERN Just another day like so many, many before..endless pain. With no leadership
1 · Reply
Latest News on GERN
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 18, 2025, 4:01 PM EDT - 18 days ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 27, 2025, 4:05 PM EDT - 5 weeks ago

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

Geron Corporation Investors: Company Investigated by the Portnoy Law Firm

Aug 14, 2025, 5:23 PM EDT - 7 weeks ago

Geron Corporation Investors: Company Investigated by the Portnoy Law Firm

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 8, 2025, 4:01 PM EDT - 2 months ago

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Geron: I Think We've Seen This Movie Before

Aug 8, 2025, 9:30 AM EDT - 2 months ago

Geron: I Think We've Seen This Movie Before

Geron Corporation (GERN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 3:01 PM EDT - 2 months ago

Geron Corporation (GERN) Q2 2025 Earnings Call Transcript

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 6, 2025, 7:01 AM EDT - 2 months ago

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Geron Appoints Harout Semerjian as President and Chief Executive Officer

Aug 6, 2025, 7:00 AM EDT - 2 months ago

Geron Appoints Harout Semerjian as President and Chief Executive Officer

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

Jul 28, 2025, 8:00 AM EDT - 2 months ago

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

Conservative Vision Of A Positive Future For Geron

Jun 3, 2025, 9:57 AM EDT - 4 months ago

Conservative Vision Of A Positive Future For Geron

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

May 28, 2025, 8:30 AM EDT - 4 months ago

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade)

May 9, 2025, 8:28 AM EDT - 5 months ago

Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade)

GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

May 8, 2025, 11:24 PM EDT - 5 months ago

GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

Geron Corporation (GERN) Q1 2025 Earnings Call Transcript

May 7, 2025, 12:50 PM EDT - 5 months ago

Geron Corporation (GERN) Q1 2025 Earnings Call Transcript

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

May 7, 2025, 12:33 PM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 7:00 AM EDT - 5 months ago

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Apr 24, 2025, 9:33 PM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 18, 2025, 4:30 PM EDT - 6 months ago

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Apr 9, 2025, 10:40 AM EDT - 6 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments

Mar 31, 2025, 4:32 PM EDT - 6 months ago

Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

Mar 31, 2025, 4:30 PM EDT - 6 months ago

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Mar 31, 2025, 2:34 PM EDT - 6 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CRVO CVS LLY NVO SEPN

Lifshitz Law PLLC Announces Investigations of Geron Corporation (NASDAQ: GERN), and The Bancorp, Inc. (NASDAQ: TBBK)

Mar 22, 2025, 12:31 PM EDT - 7 months ago

Lifshitz Law PLLC Announces Investigations of Geron Corporation (NASDAQ: GERN), and The Bancorp, Inc. (NASDAQ: TBBK)

TBBK

Geron Corp: How Concerned Should We Be About Rytelo Sales?

Mar 17, 2025, 5:19 PM EDT - 7 months ago

Geron Corp: How Concerned Should We Be About Rytelo Sales?

GERN Investors Have Opportunity to Lead the Geron Corporation Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - GERN

Mar 17, 2025, 7:42 AM EDT - 7 months ago

GERN Investors Have Opportunity to Lead the Geron Corporation Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - GERN

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Geron Corporation (GERN)

Mar 14, 2025, 3:04 PM EDT - 7 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Geron Corporation (GERN)

ZoeyTanner
ZoeyTanner Oct. 7 at 10:48 AM
$GERN Nothing here, move on. The longest wait for anything continues. The long goodbye may be in store for Harout and for BOD choice.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 7 at 1:44 AM
To us it appears that since commercial-stage oncology trades at significantly lower revenue multiples than non-oncology, oncology offers the better risk v. reward profile now that the XBI is nearing multi-year highs. Bios in both peer groups have near-tern data reads that may manifest in higher/lower revenues depending on the outcomes ($GERN $IBRX) Are we wrong? This is not investment advice. $KALV $CRMD $SLNO
0 · Reply
ZdP2
ZdP2 Oct. 6 at 10:11 PM
$GERN Seems like it wants to fill the gap to 1.2 before we go back up again. Anything below 1.3 is a great buying opportunity imho. GLTA !
0 · Reply
ZdP2
ZdP2 Oct. 6 at 7:57 PM
$GERN Large bids again...
0 · Reply
Polip
Polip Oct. 6 at 7:12 PM
$GERN idiotic short selling
2 · Reply
ZoeyTanner
ZoeyTanner Oct. 6 at 6:56 PM
$GERN Extremely bullish..give me a break..the loser of all time here with no ceo
0 · Reply
AxelWiz
AxelWiz Oct. 6 at 6:10 PM
$GERN I don’t even know why I keep looking here! This went from one of my favorite investments to one of my most hated investments, even though I’m not willing to part with it for another 3-5y
1 · Reply
ZdP2
ZdP2 Oct. 6 at 5:43 PM
$GERN About to bounce here again imo.
1 · Reply
Cello69
Cello69 Oct. 6 at 5:22 PM
$GERN Fucking worthless POS
1 · Reply
ZoeyTanner
ZoeyTanner Oct. 6 at 4:46 PM
$GERN Just another day like so many, many before..endless pain. With no leadership
1 · Reply
Winning_calls
Winning_calls Oct. 6 at 1:48 AM
$GERN pick me up @ $1.38
0 · Reply
sr7J
sr7J Oct. 5 at 12:26 AM
$GERN
0 · Reply
eunkyo
eunkyo Oct. 4 at 2:00 AM
$GERN https://www.uspto.gov/patents/laws/patent-term-extension/patent-terms-extended-under-35-usc-156?utm_source=chatgpt.com "You can check the PTE approval schedule through the following link. Currently, the most recent approval and application details were announced as of September 12th, and you can quickly find out when approval is granted by accessing it periodically."
0 · Reply
eunkyo
eunkyo Oct. 3 at 10:33 PM
$GERN https://www.clinicaltrials.gov/expert-search?term=Imetelstat "If you follow the link, it appears you can find the past and present clinical pipeline of Imetelstat along with the anticipated dates for the primary and final report schedules." This is not investment advice and may contain inaccuracies.
0 · Reply
ZdP2
ZdP2 Oct. 3 at 10:22 PM
$GERN Failed to break it today, but I think we'll make it soon. One more retrace to the green support line, and then in October we'll bust through. Jmho. GLTA !
1 · Reply
ZdP2
ZdP2 Oct. 3 at 7:58 PM
$GERN 1.5M volume in the past 10 minutes .
0 · Reply
bradbluett
bradbluett Oct. 3 at 5:08 PM
$GERN
0 · Reply
ZoeyTanner
ZoeyTanner Oct. 3 at 4:44 PM
$GERN ThIS thing is pitiful..Harout Semerjian, take a good look at Geron from the other side..any movement up, for any reason, is met by SH fleeing. Imagine a partnership or god forbid a B/O, met with selling pressure?? This is what happens when you have dead money for months and years.
2 · Reply
Radmanx
Radmanx Oct. 3 at 4:02 PM
$GERN This might just unwind back to 1.48 today 🤨
0 · Reply
Polip
Polip Oct. 3 at 4:00 PM
$GERN short sellers working overtime
1 · Reply
ZdP2
ZdP2 Oct. 3 at 3:36 PM
$GERN closed the gap to 1.38 from a few days ago. Now back up ! 🤞
0 · Reply
ZdP2
ZdP2 Oct. 3 at 3:20 PM
$GERN 1M volume in the past 20 mins. All the signs of heavy accumulation are there...
0 · Reply